Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸Á¦28Â÷ WORKSHOP Program
- ³¯Â¥: 2015³â 10¿ù 15-16ÀÏ (¸ñ-±Ý)
- Àå¼Ò: ¿©ÁÖ ½ã¹ë¸®È£ÅÚ (°æ±âµµ ¿©Áֽà °º¯À¯¿øÁö±æ 45)
- ÁÖÁ¦: Risk Mitigation Strategies in Drug Discovery and Development
|
Time |
PROGRAM |
Day 1 |
October 15, 2015 (Thursday), 2Ãþ ±×·£µåº¼·ë |
10:00-11:00 |
Registration |
11:00-11:10 |
Opening (±èµ¿È¯ ȸÀå) |
|
Key note lecture |
11:10-12:00 |
Innovative innovation in drug discovery (Çѱ¹ÈÇבּ¸¿ø ÇÏÀçµÎ ¹Ú»ç) |
12:00-12:45 |
Luncheon symposium (Sponsor: ¹ÙÀÌ¿ÀÅå½ºÅØ "¹Ì±¹ FDA Àû°Ý½ÂÀÎÀÇ ÀǹÌ" °Á¾±¸ ´ëÇ¥) |
12:45-13:30 |
Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦ |
Session 1 |
Hot topics and emerging technologies for drug development (ÁÂÀå: Àϵ¿Á¦¾à ¹Ú¼öºÀ ¹Ú»ç) |
13:30-14:15 |
Hot topics in non-clinical safety assessment of biologics (EnVigo, Mr. Lee Coney) |
14:15-15:00 |
Responses to the standard for exchange of nonclinical data (SEND) in non-US countries;
accelerate your nonclinical data submission in US and Japan (Showa University, Dr. Takayuki Anzai) |
15:00-15:20 |
Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦ |
15:20-16:05 |
Humanized-knockout zebrafish for disease models (Ãæ³²´ë ±èöÈñ ±³¼ö) |
16:05-16:50 |
SYK inhibitor for treatment of rheumatoid arthritis (¿À½ºÄÚÅØ, ±èÁßÈ£ ¹Ú»ç) |
16:50-17:35 |
Clinical application of immune checkpoint blockers into cancer immunotherapy (¿¬¼¼´ë ÇÏ»óÁØ ±³¼ö) |
17:40-18:00 |
Çѱ¹ºñÀÓ»ó½ÃÇ迬±¸È¸ ÃÑȸ |
18:00-20:00 |
Dinner & Social networking (¾ß¿Ü BBQ ¿¹Á¤) |
Day 2 |
October 16, 2015 (Friday) |
07:00-09:00 |
Breakfast |
Session 2 |
µ¶¼ººÐ°ú
(ÁÂÀå: ÇÑÈ, °í¿ì¼® ¹Ú»ç)
3Ãþ »çÆÄÀ̾î·ë
Translation of nonclinical data for clinical development |
¾àµ¿·ÂÇкаú
(ÁÂÀå: µ¿¾Æ ST, ½ÉÇöÁÖ ¹Ú»ç)
3Ãþ Å©¸®½ºÅ»·ë
Various risk mitigation strategies of PK studies |
¾àÈ¿¾à¸®ºÐ°ú
(ÁÂÀå: Çö´ë¾àǰ, ±è´ëÈÆ ¹Ú»ç)
2Ãþ ±×·£µåº¼·ë
Pharmacological approaches to reduce the drug development attrition |
09:00-09:40 |
¹ÙÀÌ¿ÀÀǾàǰ °³¹ßÀ» À§ÇÑ Àü·«Àû TCR Ȱ¿ë
(¼¿ï´ë/¿¡À̺ñ¿Â ½Å¿µ±â ±³¼ö) |
PK parameterÀÇ ½ÇÁ¦Àû ÇØ¼®: The basics and beyond
(C&C½Å¾à¿¬±¸¼Ò ±èÀ¯Ã¶ ¹Ú»ç) |
In vivo evaluation of specific gene functions in dilated cardiomyopathy and cancer
(¿¬¼¼´ë, ÀÌÇÑ¿õ ±³¼ö) |
09:40-10:20 |
Selection of the maximum recommended starting dose in first-in-human studies with biologics
(¼¿ï´ë, ÀÌÇü±â ±³¼ö) |
Practical considerations for successful quantitative bioanalysis
(¹ÙÀÌ¿ÀÄÚ¾Æ, ÀÌÈñÁÖ ¹Ú»ç) |
LC compounds as selective and efficacious oral proteasome inhibitors for multiple myeloma patients
(LG »ý¸í°úÇÐ, ¹Ú¾ï ¿¬±¸¿ø) |
10:20-10:40 |
Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦ |
10:40-11:20 |
ÀÓ»ó½ÃÇè ½ÂÀÎÀ» À§ÇÑ ºñÀÓ»ó½ÃÇè °í·Á»çÇ×
(»ç·ÊÁß½É)
(½Ä¾àó, ¹ÚÀçÇö¿¬±¸°ü) |
IVIVC ¸ðµ¨¸µÀ» ÀÌ¿ëÇÑ ¹æÃâÁ¦¾î Á¦ÇüÀÇ ¼³°è
(¼º±Õ°ü´ë, ±èÅÂȯ ¹Ú»ç) |
New drug development of a novel transient potential vanilloid type 1 (TRPV1) channel antagonist for atopic dermatitis
(¾Æ¸ð·¹ÆÛ½ÃÇÈ, ¹Ú¹Ì¿µ ¹Ú»ç) |
11:20-12:00 |
GLP µ¶¼º½ÃÇè¿¡ ÀÖ¾î¼ ºÐ¼®½ÃÇèÀÇ °³¿ä ¹×
SponsorÀÇ °í·Á»çÇ×
(KIT, Ȳ°æÈ ¹Ú»ç) |
¹æ»ç¼±µ¿À§¿ø¼Ò Ç¥Áö¹°ÁúÀ» ÀÌ¿ëÇÑ ÀüÀÓ»ó ADME ¿¬±¸½ÃÀÇ
°í·Á»çÇ×
(ÇѾç´ë À¯ÇýÇö ±³¼ö) |
Preclinical models and strategies for development of medical products targeting GI disease
(NCEED, À̵·Çà ±³¼ö) |
12:00-12:45 |
Luncheon symposium (Sponsor TS Dyne)
2Ãþ ±×·£µå º¼·ë |
12:45-13:30 |
Booth Exhibition & Coffee Break
3Ãþ ¼¼Á¾È¦ |
Session 3 |
Drug discovery and development: Successful case studies (ÁÂÀå: º¸·ÉÁ¦¾à ±è´ÞÇö ¹Ú»ç)
2Ãþ ±×·£µåº¼·ë |
13:30-14:15 |
Development strategy of an orally active drug candidate, EC-18 for chemotherapy-induced neutropenia
(¿£ÁöÄÍ, ÇÑ¿ëÇØ ¹Ú»ç) |
14:15-14:30 |
°æÇ°Ãßõ & Closing (ÀÌ»óÈ£ ºÎȸÀå) |